Rare hypertrophic cardiomyopathy

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

2 events
Dec 2023COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Bristol-Myers Squibb — NA

TrialACTIVE NOT RECRUITING
Feb 2023Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis

Far Eastern Memorial Hospital — NA

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

2

Open now

2

Copay cards

Copay Assistance2

CAMZYOS

Bristol Myers Squibb

OpenContact for detailsApply ↗

DEHYDRATED ALCOHOL

Belcher

OpenContact for details

View all support programs on disease page →

Approved Treatments

2 FDA-approved

Camzyos

(mavacamten)Orphan drugstandard

MyoKardia, Inc. (A Wholly-Owned Subsidiary of Bristol Myers Squibb)

Cardiac Myosin Inhibitor [EPC]

12.1 Mechanism of Action Mavacamten is an allosteric and reversible inhibitor selective for cardiac myosin. Mavacamten modulates the number of myosin ...

FDA label ↗

Myqorzo

(aficamten)Orphan drugstandard

Cytokinetics Inc.

12.1 Mechanism of Action Aficamten is an allosteric and reversible inhibitor of cardiac myosin motor activity. Aficamten reduces the force generated b...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1N/A
1Total recruiting
Search clinical trials for Rare hypertrophic cardiomyopathy

Recent News & Research

No recent news articles indexed yet for Rare hypertrophic cardiomyopathy.
Search PubMed for Rare hypertrophic cardiomyopathy

Browse all Rare hypertrophic cardiomyopathy news →

Specialist Network

Top 6 by expertise

View all Rare hypertrophic cardiomyopathy specialists →

Quick Actions